The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg)

Malaria Journal
Geoffrey Dow, Bryan Smith

Abstract

Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial being developed for malaria prophylaxis. It has been generally assumed that TQ, administered prophylactically, acts primarily on the developing exoerythrocytic stages of malaria parasites (causal prophylaxis), and that polymorphisms in metabolic enzymes thought to impact the activity of other 8-aminoquinolines also inhibit this property of TQ. Furthermore, it has been suggested that a diagnostic test for CYP2D6 metabolizer status might be required. In field studies in which metabolic status was not an exclusion criteria, TQ has been shown to exhibit similar prophylactic efficacy as blood schizonticidal drugs (mefloquine). Also, its blood schizonticidal and anti-relapse efficacy is independent of 2D6 metabolizer status. The most reasonable explanation for the field study results, supported by other clinical and non-clinical data, is that TQ is not completely causal and exhibits substantial blood schizonticidal activity at the intended dose. Pharmacokinetic simulations demonstrate that trough concentrations of TQ exceed the proposed MIC of 80 ng/ml in >95% of individuals. Based on these data a companion diagnostic for CP450 enzyme status is not required.

References

Jun 15, 1967·The New England Journal of Medicine·E SalvidioF Ajmar
Dec 1, 1993·Annals of Tropical Medicine and Parasitology·W PetersW K Milhous
Apr 1, 1994·The Journal of Infectious Diseases·S PukrittayakameeN J White
Feb 27, 1999·Antimicrobial Agents and Chemotherapy·J L VennerstromW K Milhous
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·Colin OhrtWilbur Milhous
Sep 13, 2002·The American Journal of Tropical Medicine and Hygiene·J Kevin BairdStephen L Hoffman
Oct 5, 2002·The American Journal of Tropical Medicine and Hygiene·Michael RamharterWalther H Wernsdorfer
Dec 23, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael D EdsteinKarl H Rieckmann
Sep 21, 2004·The Journal of Infectious Diseases·Douglas S WalshThomas G Brewer
Jun 21, 2013·Malaria Journal·Brandon S PybusVictor Melendez
Oct 4, 2013·The New England Journal of Medicine·Jason W BennettChristian F Ockenhouse
Nov 21, 2013·Journal of Travel Medicine·Gregory A Deye, Alan J Magill
May 28, 2015·The American Journal of Tropical Medicine and Hygiene·Gretchen NewbyRoly Gosling

❮ Previous
Next ❯

Citations

Sep 20, 2018·Drugs·James E Frampton
Nov 1, 2018·Journal of Travel Medicine·J Kevin Baird
Dec 12, 2020·Expert Opinion on Drug Safety·Cindy S Chu, Jimee Hwang
Feb 20, 2020·Biochemistry·Kuan-Yi Lu, Emily R Derbyshire
Mar 22, 2021·Malaria Journal·Nicholas J White

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
flow cytometry

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.